PET/CT Scan with Tracers for Prostate Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Fluciclovine F18, Axumin, Gallium Ga68-labeled PSMA-11 for prostate cancer?
Research shows that PET imaging with tracers like 18F-fluciclovine and PSMA-targeted agents, such as Gallium Ga68-labeled PSMA-11, improves disease detection rates and influences treatment planning for prostate cancer. These tracers are effective in identifying prostate cancer and have been incorporated into clinical guidelines, with early data suggesting improved patient outcomes.12345
Is the PET/CT scan with tracers for prostate cancer safe for humans?
How does the PET/CT scan with tracers for prostate cancer differ from other treatments?
The PET/CT scan with tracers for prostate cancer is unique because it uses specific tracers like 68Ga-PSMA-11 and 18F-PSMA-11, which are designed to target prostate-specific membrane antigen (PSMA), making it highly sensitive and specific for detecting prostate cancer. This imaging method is particularly useful for identifying both primary tumors and metastatic lesions, offering a more precise diagnosis compared to traditional imaging techniques.136910
Research Team
Ashesh Jani, MD, MSEE
Principal Investigator
Emory University
Eligibility Criteria
This trial is for men with prostate adenocarcinoma who've had surgery but still have detectable PSA levels, no signs of metastasis outside the pelvis or in bones, and can perform daily activities (ECOG 0-2). They must be willing to undergo pelvic radiotherapy and not have other recent cancers or severe illnesses like heart failure, infections needing IV antibiotics, severe lung disease, AIDS, or conditions that prevent radiation therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Treatment Planning
Participants receive either fluciclovine F18 or 68Ga-PSMA intravenously and undergo PET/CT scans to plan radiation treatments
Radiation Treatment
Radiation treatment is administered based on PET/CT imaging results
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Fluciclovine F18
- Gallium Ga68-labeled PSMA-11
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry Sponsor
National Institutes of Health (NIH)
Collaborator
Telix International Pty Ltd
Industry Sponsor
National Cancer Institute (NCI)
Collaborator